A Phase 3 interventional study of Reference Drug and SMO1 in Retinal Vein Occlusion With Macular Edema, sponsored by SANGMYUNG innovation. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by SANGMYUNG innovation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Macular Edema with a site in Korea, Republic of — 1 open to participants now, 2 under way, 1 of them phase 3. Macular Edema · Korea, Republic of.
Among the 38 studies in Macular Edema with a site in Korea, Republic of, this one is the 11th largest by planned enrollment of the 35 interventional ones that give a count, is the only one that started in 2026, is one of 16 in phase 3, and was the 38th registered.
759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →1 of the 38 studies in Macular Edema with a site in Korea, Republic of is open now.
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 17 · Phase 4 9
First in 2004; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 312 is above the median of 56 across 587 interventional studies indexed under Macular Edema.
Median enrollment 100 across the 35 interventional studies, 87 across the 1 observational. Of the 27 that completed or were terminated, 14 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 38 have an industry lead sponsor. The 10 most frequent:
SANGMYUNG innovation is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
SANGMYUNG innovation has 1 study filed under Macular Edema — fewer than ten, so there is no comparison to draw.
1 of the studies in Macular Edema with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07708142Phase 3SANGMYUNG innovationEfficacy and Safety Evaluation of SMO1 in Patients With Retinal Vein Occlusive Macular Edema | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 38 studies in Macular Edema with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-masked, parallel-group, active-controlled Phase 3 clinical trial designed to evaluate the efficacy and safety of SMO1 (Dexamethasone 700μg intravitreal implant) compared with the reference drug (Dexamethasone 700μg intravitreal implant) in patients with retinal vein occlusion (RVO)-associated macular edema.
Participants are randomized in a 1:1 ratio to receive either the reference drug or the investigational product, SMO1, following screening and baseline assesments. Randomization is centrally managed and stratified by RVO subtype (branch or central). Patients are followed for 6 months with scheduled visits to assess efficacy and safety endpoints. A total of 312 participants (156 per treatment arm) will be enrolled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment: Reference Drug (Dexamethasone 700μg Intravitreal Implant) Pre-treatment: Ofloxacin (3mg/mL) Eye Drop
Drug: Reference Drug
Treatment: SMO1 (Dexamethasone 700μg Intravitreal Implant) Pre-treatment: Ofloxacin (3mg/mL) Eye Drop
Drug: SMO1
1. Pre-treatment: Ofloxacin Eye Drop TID for 3 days before and after the administration of the reference drug (Day -3 \~ 3). 2. Single administration of the reference drug at Day 0.
1\. Pre-treatment: Ofloxacin Eye Drop TID for 3 days before and after the administration of the reference drug (Day -3 \~ 3). 2. Single administration of SMO1 at Day 0.
Best corrected visual acuity (BCVA) at Month 2
Change in BCVA score from the baseline, at Month 2 after the administration of the investigational drug using early treatment diabetic retinopathy study (ETDRS) chart
Time frame: Month 2
BCVA at Month 1, 3, and 6
Change in BCVA score from the baseline, at Month 1, 3, and 6 after the administration of the investigational drug using ETDRS chart
Time frame: Month 1, 3, and 6
BCVA improvement of 15 letters (3 lines) or more
Proportion of patients with BCVA improvement of 15 letters (3 lines) or more compared to the baseline using ETDRS chart, at each post-administration visit (Month 1, 2, 3, and 6)
Time frame: Month 1, 2, 3, and 6
Central retinal thickness (CRT) at each visit
Change in CRT compared to the baseline measured with optical coherence tomography (OCT), at each post-administration visit (Month 1, 2, 3, and 6)
Time frame: Month 1, 2, 3, and 6
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jul 2027, 18 months after the start.
Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's planned 18 months is below that.
Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
SANGMYUNG innovation